CHOLANGIO
TODAY
Patient-Led Understanding
Understanding changes what happens next.
Patient-Led investigations into cholangiocarcinoma, cancer biology and the consequential questions that matter when the patient carries the consequence.
LATEST INVESTIGATION
PD-L1 Negative: Can Immunotherapy Still Work? | Cholangio Today
Why do some patients classified as PD-L1 negative still respond to immunotherapy? Steve Holmes investigates the clinical evidence, immune checkpoint biology and what these findings could mean for patients with cholangiocarcinoma.
CHOLANGIO TODAY
Earlier Investigations
ATM Mutation in Cancer: What It Means and Why Context Matters
ATM mutation in cancer is often misunderstood. This article explains what ATM really means, why it appears, and why biological context matters more than the gene itself.